Prognostic factors of exosomes in coronary heart disease and related diseases

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025296

Enrollment

Unknown

Registered

2019-08-21

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Case series:N/A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years and < 80 years; 2. Clinical diagnosis included non-ST-segment elevation acute myocardial infarction, ST-segment elevation acute myocardial infarction, stable angina pectoris and unstable angina pectoris. 3. Coronary angiography confirmed that at least one major coronary artery stenosis was more than 50%. 4. Ability to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Complicated with severe valvular heart disease. 2. Complicated with severe congenital heart disease. 3. Complicated with hyperthyroidism, anemia and other hyperdynamic heart disease. 4. Complicated with pulmonary heart disease. 5. Complicated with hypertrophic obstructive cardiomyopathy. 6. Severe hypotension (SBP 160 mmHg and/or DBP > 100 mmHg before PCI). 8. Liver dysfunction (defined as ALT or total bilirubin greater than three times the normal upper limit). 9. Renal insufficiency (defined as creatinine greater than 1.5 times the normal upper limit). 10. Patients at high risk of bleeding, such as thrombocytopenia, hematological diseases, etc. 11. Active peptic ulcer and skin ulcer. 12. Patients allergic to clopidogrel, tegrel and aspirin. 13. Patients with a history of cardiogenic shock within two weeks. 14. Pregnant and lactating women, women of childbearing age who cannot be strictly contraceptive during treatment. 15. Patients with malignant tumors. 16. Participated in other clinical researchers in the past three months. 17. Those who do not have legal capacity or whose legal capacity is limited. 18. Researchers do not consider it appropriate to participate in any of the clinical studies.

Design outcomes

Primary

Measure	Time frame
all-cause mortality;Cardiac mortality;stroke;BARC2 or more bleeding events;readmission;Target vessel revascularization;Recurrent myocardial infarction;Stent thrombosis;Heart Failure;	—

Countries

China

Contacts

Public ContactZhang Jinying, Tang Junnan

The First Affiliated Hospital of Zhengzhou University

jyzhang@zzu.edu.cn+86 13503830283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026